BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) Two-Notches to Underperform
ACHN Hot Sheet
Rating Summary:10 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
BofA/Merrill Lynch downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Underperform.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $11.57 yesterday, with a 52 week range of $3.81-$12.95.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $11.57 yesterday, with a 52 week range of $3.81-$12.95.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Wedbush Downgrades Maxwell Technologies (MXWL) to Neutral; Elevated Competitive and Supply Chain Risks
- Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
Merrill Lynch, Bank of AmericaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
